REMED (302550) Financial Statements

OverviewFinancialsChecksFilings

In fiscal year 2025, REMED (302550) reported revenue of 24.5 billion KRW.

Income Statement

YearRevenueOp ProfitNet IncomeSource
202524.5 billion KRW726 million KRW-35 million KRW[source]
202425.6 billion KRW1.1 billion KRW7.4 billion KRW[source]
202318.5 billion KRW-2.9 billion KRW319 million KRW[source]
202221.4 billion KRW1.7 billion KRW4.0 billion KRW[source]
202120.2 billion KRW1.1 billion KRW752 million KRW[source]

Balance Sheet

YearTotal AssetsTotal LiabilitiesTotal EquitySource
202554.1 billion KRW10.5 billion KRW43.6 billion KRW[source]
202457.4 billion KRW15.0 billion KRW42.4 billion KRW[source]
202354.4 billion KRW20.4 billion KRW34.0 billion KRW[source]
202279.3 billion KRW47.9 billion KRW31.4 billion KRW[source]
202178.0 billion KRW50.9 billion KRW27.1 billion KRW[source]

Cash Flow

YearOperatingInvestingFinancingSource
20252.4 billion KRW4.6 billion KRW-4.2 billion KRW[source]
20241.2 billion KRW6.5 billion KRW-6.8 billion KRW[source]
20233.5 billion KRW21.1 billion KRW-25.0 billion KRW[source]
20225.2 billion KRW-10.2 billion KRW-9 million KRW[source]
2021-3.5 billion KRW2.9 billion KRW490 million KRW[source]
Financials & Filings: DART (traceable by receipt number) · Prices: Financial Services Commission · Data Sources · Last checked: 2026-08-29 · About · Delisting market cap threshold: KOSPI 5B KRW / KOSDAQ 4B KRW (per listing rules) · This page provides factual information, not investment advice